The Rodenstock Group, a global leader in eye health innovation and manufacturer of biometric, ophthalmic lenses, today announced the appointment of two industry experts to its newly created Advisory Board.
The Advisory Board is designed to provide senior advice and counsel to the company’s management on its path to successfully transform and grow Rodenstock in years to come.
Guillaume Daniellot, CEO of Straumann Group, a global leader in premium tooth replacement solutions, said on his appointment: “I am excited to join Rodenstock’s Advisory Board. There are many learnings from Straumann. Rodenstock is focused on providing superior visual precision and comfort to its end customers via partnering with opticians in this consumer Med-Tech model. This is very similar to what Straumann does in the tooth replacement business.”
Dr. Theo Kiesselbach, independent advisor and former CEO of GrandVision added: “During my now nearly 20-year career in the optical industry, Rodenstock has always impressed me as a reliable partner to the optician, provider of premium products and services, and a strong innovator. As a member of the Advisory Board, I look forward to contributing to Rodenstock’s next phase of further excelling in these areas.”
The board will be chaired by Dr. Steven Dyson, Partner in the Healthcare team of Apax, and complemented by Camilla Macapili Languille and Mina Abdulla Hamoodi from Mubadala, as well as Mehmet Tar from Apax.
“We are delighted to have such an experienced team join our new Advisory Board. With their profound industry insight and market experience, Guillaume and Theo will help us drive the next steps of Rodenstock’s transformation process and strengthen our position as a leading consumer Med-Tech company”, says Rodenstock CEO Anders Hedegaard.